Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

被引：54
|
作者：
Boeckx, Carolien [1 ]
de Beeck, Ken Op [1 ,2 ,3 ]
Wouters, An [1 ]
Deschoolmeester, Vanessa [1 ]
Limame, Ridha [1 ]
Zwaenepoel, Karen [4 ]
Specenier, Pol [1 ,5 ]
Pauwels, Patrick [1 ,4 ]
Vermorken, Jan B. [1 ,5 ]
Peeters, Marc [1 ,5 ]
Van Camp, Guy [2 ,3 ]
Baay, Marc [1 ]
Lardon, Filip [1 ]
机构：
[1] Univ Antwerp, CORE Antwerp, Lab Canc Res & Clin Oncol, Antwerp, Belgium
[2] Univ Antwerp, Ctr Med Genet, Dept Biomed Sci, Antwerp, Belgium
[3] Univ Antwerp Hosp, Antwerp, Belgium
[4] Univ Antwerp Hosp, Dept Pathol, Antwerp, Belgium
[5] Univ Antwerp Hosp, Dept Med Oncol, Antwerp, Belgium
来源：
CANCER LETTERS | 2014年 / 354卷 / 02期
关键词：
Head and neck squamous cell carcinoma; Anti-EGFR therapy; Cetuximab resistance; Dual-specificity phosphatase 5 and 6; Aurora kinase B; Nano Pro 1000; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; APIGENIN INDUCES APOPTOSIS; NECK-CANCER; COLORECTAL-CANCER; PANCREATIC-CANCER; MESENCHYMAL TRANSITION; AURORA KINASES; MONOCLONAL-ANTIBODY;
D O I：
10.1016/j.canlet.2014.08.039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Unraveling the underlying mechanisms of cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) is of major importance as many tumors remain non-responsive or become resistant. Our microarray results suggest that "resistant" cells still exhibit RAS-MAPK pathway signaling contributing to drug resistance, as witnessed by low expression of DUSP5 and DUSP6, negative regulators of ERK1/2, and increased expression of AURKB, a key regulator of mitosis. Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCc. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：365 / 377
页数：13
相关论文
共 50 条
  • [31] Role of integrated cancer nanomedicine in overcoming drug resistance
    Iyer, Arun K.
    Singh, Amit
    Ganta, Srinivas
    Amiji, Mansoor M.
    ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (13-14) : 1784 - 1802
  • [32] The role of photodynamic therapy in overcoming cancer drug resistance
    Bryan Q. Spring
    Imran Rizvi
    Nan Xu
    Tayyaba Hasan
    Photochemical & Photobiological Sciences, 2015, 14 : 1476 - 1491
  • [33] The role of brand in overcoming consumer resistance to autonomous vehicles
    Casidy, Riza
    Claudy, Marius
    Heidenreich, Sven
    Camurdan, Efe
    PSYCHOLOGY & MARKETING, 2021, 38 (07) : 1101 - 1121
  • [34] Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
    Iida, Mari
    Brand, Toni M.
    Starr, Megan M.
    Huppert, Evan J.
    Luthar, Neha
    Bahrar, Harsh
    Coan, John P.
    Pearson, Hannah E.
    Salgia, Ravi
    Wheeler, Deric L.
    MOLECULAR CANCER, 2014, 13
  • [35] Overcoming acquired resistance to cetuximab by dual targeting of HER family members using antibody based therapy
    Iida, Mari
    Brand, Toni M.
    Starr, Megan M.
    Luthar, Neha
    Wleklinski, Matthew J.
    Wheeler, Deric L.
    CANCER RESEARCH, 2013, 73 (08)
  • [36] Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
    Mari Iida
    Toni M Brand
    Megan M Starr
    Evan J Huppert
    Neha Luthar
    Harsh Bahrar
    John P Coan
    Hannah E Pearson
    Ravi Salgia
    Deric L Wheeler
    Molecular Cancer, 13
  • [37] Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
    Rathore, Rama
    McCallum, Jennifer E.
    Varghese, Elizabeth
    Florea, Ana-Maria
    Busselberg, Dietrich
    APOPTOSIS, 2017, 22 (07) : 898 - 919
  • [38] Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
    Rama Rathore
    Jennifer E. McCallum
    Elizabeth Varghese
    Ana-Maria Florea
    Dietrich Büsselberg
    Apoptosis, 2017, 22 : 898 - 919
  • [39] Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
    D L Wheeler
    S Huang
    T J Kruser
    M M Nechrebecki
    E A Armstrong
    S Benavente
    V Gondi
    K-T Hsu
    P M Harari
    Oncogene, 2008, 27 : 3944 - 3956
  • [40] Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
    Wheeler, D. L.
    Huang, S.
    Kruser, T. J.
    Nechrebecki, M. M.
    Armstrong, E. A.
    Benavente, S.
    Gondi, V.
    Hsu, K-T
    Harari, P. M.
    ONCOGENE, 2008, 27 (28) : 3944 - 3956
12345